Recap: Vanda Pharmaceuticals Q4 Earnings
Recap: Vanda Pharmaceuticals Q4 Earnings
Shares of Vanda Pharmaceuticals (NASDAQ:VNDA) increased in after-market trading after the company reported Q4 results.
的股份万达制药(纳斯达克:VNDA)在该公司公布第四季度业绩后,盘后交易增加。
Quarterly Results
季度业绩
Earnings per share increased 87.50% over the past year to $0.15, which beat the estimate of $0.14.
每股收益在过去一年中增长了87.50%,达到0.15美元,超过了0.14美元的预期。
Revenue of $67,653,000 rose by 11.03% from the same period last year, which beat the estimate of $64,000,000.
营收为67,653,000美元,较去年同期增长11.03%,超过预期的64,000,000美元。
Guidance
导向
Earnings guidance hasn't been issued by the company for now.
该公司目前尚未发布盈利指引。
The upcoming fiscal year's revenue expected to be between $270,000,000 and $300,000,000.
下一财年的收入预计在2.7亿美元至3亿美元之间。
How To Listen To The Conference Call
如何收听电话会议
Date: Feb 10, 2021
日期:2021年2月10日
Time: 04:30 PM
时间:下午4时30分
ET Webcast URL: https://edge.media-server.com/mmc/p/3jdd3b89
Price Action
价格行动
52-week high: $16.29
52周高点:16.29美元
Company's 52-week low was at $7.12
该公司52周低点为7.12美元
Price action over last quarter: Up 40.22%
上季度价格走势:上涨40.22%
Company Description
公司描述
Vanda Pharmaceuticals Inc is a biopharmaceutical company which is engaged in the development and commercialization of therapies to address high unmet medical needs and improves the lives of patients. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant (VLY-686), VTR-297, and VQW-765.
万达制药公司是一家生物制药公司,致力于药物的开发和商业化,以满足高度未得到满足的医疗需求,并改善患者的生活。其产品组合包括Hetlioz、Fanapt、传统型(VLY-686)、录像机-297和VQW-765。
译文内容由第三方软件翻译。